Impact of Pap Test Compliance and Cervical Cancer Screening Intervals on Human Papillomavirus Vaccine Acceptance

被引:3
作者
Ferris, Daron G. [1 ,2 ,3 ]
Waller, Jennifer [4 ]
Dickinson, Ashley
McCracken, Courtney
Goebel, Angela [1 ,2 ]
机构
[1] Georgia Hlth Sci Univ, Gynecol Canc Prevent Ctr, Augusta, GA 30912 USA
[2] Georgia Hlth Sci Univ, Dept Family Med, Augusta, GA 30912 USA
[3] Georgia Hlth Sci Univ, Dept Obstet & Gynecol, Augusta, GA 30912 USA
[4] Georgia Hlth Sci Univ, Dept Biostat, Augusta, GA 30912 USA
关键词
human papillomavirus; vaccine; acceptance; Pap test interval; Pap test compliance; QUADRIVALENT VACCINE; PARTICLE VACCINE; HPV VACCINE; EFFICACY;
D O I
10.1097/LGT.0b013e31822e8e25
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives. The objective of this study was to determine the impact of Pap test compliance and cervical cancer screening intervals on human papillomavirus (HPV) vaccination acceptance. Materials and Methods. A convenience sample of 499 women 21 to 65 years old completed a 37-question survey in Augusta and Savannah, GA. The survey assessed their knowledge about HPV, cervical cancer, and the HPV vaccine. The questionnaire also determined their Pap test compliance and how longer Pap test intervals would influence their willingness to receive the HPV vaccine. Differences between categorical variables and knowledge scores were examined using chi(2) test and unequal-variance t tests, respectively. Results. Pap test-noncompliant women were more likely to get the HPV vaccine if they only needed a Pap test every 10 years compared with Pap test-compliant women (27.6% vs 14.6%, p = .02). A greater number (83.5%) of Pap test-noncompliant women preferred the HPV vaccine plus every 10-year Pap test option compared with Pap test-compliant women (31.3%, p < .0001). Most women (87%) responded that they would likely get the HPV vaccine if it would safely reduce the frequency of Pap testing. Conclusions. Women are receptive to getting the HPV vaccine in exchange for longer cervical cancer screening intervals. Moreover, Pap test-noncompliant women are more likely to get the HPV vaccine if Pap testing was needed less frequently. Increasing the Pap testing interval may be an excellent method to improving HPV vaccine acceptance in women at highest risk for cervical cancer.
引用
收藏
页码:39 / 44
页数:6
相关论文
共 12 条
  • [1] Davis Kristin, 2004, J Low Genit Tract Dis, V8, P188, DOI 10.1097/00128360-200407000-00005
  • [2] Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume - Projections from the National Health Interview Survey (MMIS)
    Eltoum, Isam A.
    Roberson, Janie
    [J]. CANCER CYTOPATHOLOGY, 2007, 111 (01) : 34 - 40
  • [3] Ferris Daron G, 2007, J Low Genit Tract Dis, V11, P166, DOI 10.1097/lgt.0b013e3180324114
  • [4] Men's Attitudes Toward Receiving the Human Papillomavirus Vaccine
    Ferris, Daron G.
    Waller, Jennifer L.
    Miller, Jeremiah
    Patel, Pratik
    Jackson, Lanier
    Price, George A.
    Wilson, Courtesia
    [J]. JOURNAL OF LOWER GENITAL TRACT DISEASE, 2008, 12 (04) : 276 - 281
  • [5] Ferris DG, 2010, INT PAP M MONTR CAN
  • [6] Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
    Garland, Suzanne M.
    Hernandez-Avila, Mauricio
    Wheeler, Cosette M.
    Perez, Gonzalo
    Harper, Diane M.
    Leodolter, Sepp
    Tang, Grace W. K.
    Ferris, Daron G.
    Steben, Marc
    Bryan, Janine
    Taddeo, Frank J.
    Railkar, Radha
    Esser, Mark T.
    Sings, Heather L.
    Nelson, Micki
    Boslego, John
    Sattler, Carlos
    Barr, Eliav
    Koutsky, Laura A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (19) : 1928 - 1943
  • [7] Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males
    Giuliano, Anna R.
    Palefsky, Joel M.
    Goldstone, Stephen
    Moreira, Edson D., Jr.
    Penny, Mary E.
    Aranda, Carlos
    Vardas, Eftyhia
    Moi, Harald
    Jessen, Heiko
    Hillman, Richard
    Chang, Yen-Hwa
    Ferris, Daron
    Rouleau, Danielle
    Bryan, Janine
    Marshall, J. Brooke
    Vuocolo, Scott
    Barr, Eliav
    Radley, David
    Haupt, Richard M.
    Guris, Dalya
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (05) : 401 - 411
  • [8] Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
    Paovonen, J.
    Naud, P.
    Salmeron, J.
    Wheeler, C. M.
    Chow, S-N
    Apter, D.
    Kitchener, H.
    Castellsague, X.
    Teixeira, J. C.
    Skinner, S. R.
    Hedrick, J.
    Jaisamrarn, U.
    Limson, G.
    Garland, S.
    Szarewski, A.
    Romanowski, B.
    Aoki, F. Y.
    Schwarz, T. F.
    Poppe, W. A. J.
    Bosch, F. X.
    Jenkins, D.
    Hardt, K.
    Zahaf, T.
    Descamps, D.
    Struyf, F.
    Lehtinen, M.
    Dubin, G.
    [J]. LANCET, 2009, 374 (9686) : 301 - 314
  • [9] Philips C, USE ACCEPTANCE HPV V
  • [10] Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ:: a combined analysis of four randomised clinical trials
    Villa, L.
    Perez, G.
    Kjaer, S.
    Lehtinen, M.
    Paavonen, J.
    Munoz, N.
    Sigurdsson, K.
    Hernandez-Avila, M.
    Iversen, O. E.
    Thoresen, S.
    Garcia, P.
    Majewski, S.
    Tay, E. H.
    Bosch, F. X.
    Dillner, J.
    Olsson, S. E.
    Ault, K.
    Brown, D.
    Ferris, D.
    Giuliano, A.
    Koutsky, L.
    Kurman, R.
    Myers, E.
    Barr, E.
    Boslego, J.
    Bryan, J.
    Esser, M.
    Hesley, T.
    Lupinacci, L.
    Railkar, R.
    Sings, H.
    Taddeo, F.
    Thornton, A.
    [J]. LANCET, 2007, 369 (9576) : 1861 - 1868